RE:Lipid Delivery Licences Can Be Valuable!Javaman,I agree with you.DPX has tremendous potential and management is doing great PR work promoting the benefits.No comparison to the lacklustre effort of IMV.
Merck financed the start of the clinical trials for ovarian cancer and experienced first hand the benefits of DPX technology.Unfortunately the trials only had a handful of patients and even with encouraging results,Merck walked away and was likely due in part to the failure of management to meet expectations.
Hope the current management keeps up with their initial impressive performance.